|drug628||Placebo plus standard preventive measures Wiki||1.00|
|drug627||Placebo oral tablet Wiki||0.22|
|D045169||Severe Acute Respiratory Syndrome NIH||0.07|
|D018352||Coronavirus Infections NIH||0.06|
There is one clinical trial.
This COVID-19 pandemic warrants urgent strategies to protect people at high risk of infection, particularly the healthcare workers. Secondary prevention through post-exposure prophylaxis (PEP) and early treatment of infection are needed to prevent severe cases and cut secondary transmission. Hydroxycholoroquine (HCQ) is an inexpensive anti-malarial drug with immunomodulatory effects that are currently used as an off-label treatment for symptomatic COVID-19 patients. In vitro studies have shown that it can efficiently inhibit SARS-CoV-2 infection and has potential as a post-exposure prophylaxis drug.
Description: Incidence of COVID-19 infection confirmed by RT-PCR COVID-19 test within the PEP treatment period (28 days) with or without symptoms of COVID-19 infectionMeasure: Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection Time: 30 days
Description: Incidence of patient self-reported COVID-19 related symptoms anytime during follow up period as measured by a standardized patient diaryMeasure: Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events) Time: 30 days
Description: Interval from exposure to COVID-19 case Interval from first dose of study drugMeasure: Time to COVID-19 infection in patients receiving study drug (in days) Time: 30 days
Description: Incidence of study drug discontinuation Incidence of all adverse events based on patients a) self-report using daily symptom diary and b) study physiciansMeasure: Safety and tolerability of study drug (to be reported as absolute number and frequency of events) Time: 30 days